2023
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma. Future Oncology 2023, 20: 317-328. PMID: 38050764, DOI: 10.2217/fon-2023-0191.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaReal-world treatment patternsLarge B-cell lymphomaB-cell lymphomaTreatment patternsMedicare beneficiariesFirst-line treatmentFront-line treatmentHealthcare resource useHealth resource useElderly Medicare beneficiariesUnmet need existsOverall survivalR-CHOPMedicare patientsLater linesOlder adultsTreatmentPatientsLymphomaNeed existsSurvivalTwo-thirdsResource useSame periodIbrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2286-2295. PMID: 37870435, DOI: 10.1080/10428194.2023.2256911.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaIbrutinib discontinuationLymphocytic leukemiaHalf of patientsMonths of initiationElderly Medicare beneficiariesLarge unmet needPart D low-income subsidyLow-income subsidyCardiovascular comorbiditiesElderly patientsReal-world practiceIbrutinib treatmentLymphocytic lymphomaAdvanced ageClinical trialsMedical CenterMedicare claimsDiscontinuationHigh riskMedicare beneficiariesUnmet needPatientsLeukemiaTwo-thirdsAssessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs. Leukemia & Lymphoma 2023, 64: 1752-1770. PMID: 37497877, DOI: 10.1080/10428194.2023.2234525.Peer-Reviewed Original ResearchConceptsHealthcare resource utilizationMantle cell lymphomaElderly patientsTreatment patternsCell lymphomaUnmet needLater linesNational Medicare claimsHalf of patientsHealth care utilizationElderly Medicare beneficiariesLarge unmet needReal-world outcomesCause hospitalizationOverall survivalCare utilizationHospitalization ratesNovel therapiesMedicare claimsL regimenHealthcare costsMedicare beneficiariesL treatmentPatientsLymphoma
2022
Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study
Huntington S, De Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Yang X, Doshi J. Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study. Blood 2022, 140: 7939-7940. DOI: 10.1182/blood-2022-155903.Peer-Reviewed Original Research